[HTML][HTML] High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib
…, F Cavalca, B Bellosillo, L Benajiba, N Curto-Garcia… - Leukemia, 2021 - nature.com
We report the clinical presentation and risk factors for survival in 175 patients with
myeloproliferative neoplasms (MPN) and COVID-19, diagnosed between February and June 2020. …
myeloproliferative neoplasms (MPN) and COVID-19, diagnosed between February and June 2020. …
[HTML][HTML] Ruxolitinib versus best available therapy for polycythemia vera intolerant or resistant to hydroxycarbamide in a randomized trial
…, WG Dunn, E Nadezhdin, N Curto-Garcia… - Journal of Clinical …, 2023 - ncbi.nlm.nih.gov
… Dunn, MB ChB, 4 Eugene Nadezhdin, PhD, 3 Natalia Curto-Garcia, MB BCh, MRCPath, 1
Anna Green, MB BS, 1 Bridget Wilkins, PhD, MRCPath, 1 Jason Coppell, MBBS, 11 John Laurie …
Anna Green, MB BS, 1 Bridget Wilkins, PhD, MRCPath, 1 Jason Coppell, MBBS, 11 John Laurie …
Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) induces neutralising antibody and polyfunctional …
…, J Saunders, N Curto-Garcia… - British journal of …, 2021 - Wiley Online Library
Patients receiving targeted cancer treatments such as tyrosine kinase inhibitors (TKIs) have
been classified in the clinically extremely vulnerable group to develop severe acute …
been classified in the clinically extremely vulnerable group to develop severe acute …
[HTML][HTML] Single dose of BNT162b2 mRNA vaccine against SARS-CoV-2 induces high frequency of neutralising antibody and polyfunctional T-cell responses in …
…, A Espehana, C Woodley, J Saunders, N Curto-Garcia… - Leukemia, 2021 - nature.com
Encouraging results have been observed from initial studies evaluating vaccines targeting
the novel beta coronavirus which causes severe acute respiratory syndrome coronavirus 2 (…
the novel beta coronavirus which causes severe acute respiratory syndrome coronavirus 2 (…
[HTML][HTML] MANIFEST: Pelabresib in combination with ruxolitinib for Janus kinase inhibitor treatment-naïve myelofibrosis
…, S Verstovsek, N Curto-García… - Journal of Clinical …, 2023 - ncbi.nlm.nih.gov
PURPOSE Standard therapy for myelofibrosis comprises Janus kinase inhibitors (JAKis),
yet spleen response rates of 30%-40%, high discontinuation rates, and a lack of disease …
yet spleen response rates of 30%-40%, high discontinuation rates, and a lack of disease …
Splanchnic vein thromboses associated with myeloproliferative neoplasms: an international, retrospective study on 518 cases
…, N Lavi, CN Harrison, N Curto‐Garcia… - American journal of …, 2020 - Wiley Online Library
Myeloproliferative Neoplasms (MPN) course can be complicated by thrombosis involving
unusual sites as the splanchnic veins (SVT). Their management is challenging, given their …
unusual sites as the splanchnic veins (SVT). Their management is challenging, given their …
[HTML][HTML] Characteristics and outcomes of patients with essential thrombocythemia or polycythemia vera diagnosed before 20 years of age: a systematic review
JC Ianotto, N Curto-Garcia, M Lauermanova… - …, 2019 - ncbi.nlm.nih.gov
Although it is well known that myeloproliferative neoplasms occur in younger patients, few
large cohorts of such patients have been reported. Thus, our knowledge about circumstances …
large cohorts of such patients have been reported. Thus, our knowledge about circumstances …
[HTML][HTML] Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19
…, B Bellosillo, L Benajiba, N Curto-Garcia… - Blood cancer …, 2021 - nature.com
In a multicenter European retrospective study including 162 patients with COVID-19 occurring
in essential thrombocythemia (ET, n = 48), polycythemia vera (PV, n = 42), myelofibrosis (…
in essential thrombocythemia (ET, n = 48), polycythemia vera (PV, n = 42), myelofibrosis (…
Real-world study of children and young adults with myeloproliferative neoplasms: identifying risks and unmet needs
…, JJ Kiladjian, Y Beauverd, N Curto-Garcia… - Blood …, 2022 - ashpublications.org
Myeloproliferative neoplasms (MPNs) are uncommon in children/young adults. Here, we
present data on unselected patients diagnosed before 25 years of age included from 38 centers …
present data on unselected patients diagnosed before 25 years of age included from 38 centers …
[HTML][HTML] Pelabresib (CPI-0610) monotherapy in patients with myelofibrosis-update of clinical and translational data from the ongoing manifest trial
…, W Prejzner, LL Teichmann, N Curto-Garcia… - Blood, 2021 - Elsevier
Background: Pelabresib (CPI-0610) is a potent, first-in-class, selective, oral small-molecule
inhibitor of bromodomain and extraterminal domain (BET) proteins which is able to modify …
inhibitor of bromodomain and extraterminal domain (BET) proteins which is able to modify …
